LLY - Eli Lilly and Company

NYSE - Nasdaq Real Time Price. Currency in USD
-1.52 (-0.36%)
At close: 04:01PM EDT
424.75 -1.04 (-0.24%)
After hours: 07:56PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close427.31
Bid401.00 x 800
Ask426.65 x 800
Day's Range423.67 - 431.67
52 Week Range283.11 - 454.95
Avg. Volume3,308,362
Market Cap404.191B
Beta (5Y Monthly)0.37
PE Ratio (TTM)67.59
EPS (TTM)6.30
Earnings DateAug 08, 2023
Forward Dividend & Yield4.52 (1.06%)
Ex-Dividend DateMay 12, 2023
1y Target Est436.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
12% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for LLY

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Simply Wall St.

    Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

    Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$373 Current share price of...

  • Investor's Business Daily

    Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

    An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

  • Insider Monkey

    Louis Navellier’s 2023 Portfolio: 15 Growth Stocks to Watch

    In this article, we discuss 15 growth stocks to watch in Louis Navellier’s 2023 portfolio. If you want to see more stocks in this selection, check out Louis Navellier’s 2023 Portfolio: 5 Growth Stocks to Watch. According to a report featured on Markets Insider in October 2022, Louis Navellier of Navellier & Associates said that the […]

  • Insider Monkey

    12 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain

    In this article, we discuss 12 best growth stocks to buy and hold in 2023 according to billionaire Rajiv Jain. If you want to see more stocks in this selection, check out 5 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain. Bloomberg reported on May 23 that Rajiv Jain, […]

  • Financial Times

    No ‘magic wand’ for financial pressures, Hunt tells pharma groups

    UK chancellor Jeremy Hunt has told drugmakers that the government has no “magic wand” to deal with financial pressures and was unlikely to give into industry demands to pay a significantly higher price for medicines. The government will on Friday unveil reforms worth £650mn to boost the life sciences sector as part of a wider package of measures. Drugmakers have condemned the government for this year increasing a tax on sales of drugs to the NHS to 26.5 per cent, from 5.1 per cent over the past two years.

  • InvestorPlace

    7 Stocks to Buy for This ‘Washing Machine’ Market

    Do you know what a “washing machine” market looks like? If not, look around, because you’re in one now. A washing machine market is what I call a stock market that is sloshing prices back and forth without picking up any real momentum. Gains in one S&P 500 sector are swallowed by losses in another. Some days the Dow Jones Industrial Average may be up, but the Nasdaq composite will be down. A washing machine market can frustrate some, but I enjoy looking for fundamentally superior stocks to get m

  • Reuters

    UPDATE 1-AbCellera to make C$701 million co-investment in Canada

    AbCellera Biologics said on Wednesday it will make a C$701 million ($515.6 million) co-investment with the governments of Canada and British Columbia to strengthen capabilities for drug development, manufacturing and clinical research in the country. Over the next eight years, the company will invest C$401 million in the project, and the governments of Canada and British Columbia will contribute C$225 million and C$75 million, respectively.

  • Insider Monkey

    14 Best Healthcare Dividend Stocks to Buy

    In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]

  • InvestorPlace

    7 Stocks That Could Be the Next $2 Trillion-Dollar Companies

    As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN) and Apple (NASDAQ:AAPL) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time. Subsequently, both overcame the $2 trillion mark, and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) has also joined the $1 trillion club. I guess it’s natural that the first companies to cross that huge $1 trilli

  • Zacks

    Pfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up

    Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.

  • Insider Monkey

    Hers’s Why Eli Lilly and Company (LLY) Declined in Q1

    Fred Alger Management, an investment management company, released its “Alger Spectra Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, Class A shares of the fund underperformed the Russell 3000 Growth Index and returned 7.98% (with sales charges) compared to the Index return of 13.85%. Consumer […]

  • The Wall Street Journal

    Ozempic: How the Diabetes Drug Works and Why It’s Such a Big Deal for Weight Loss

    WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. A drug approved by the Food and Drug Administration to treat people with Type 2 diabetes has ignited a craze among social-media influencers, the rich and famous and everyday people alike. Ozempic, made by Novo Nordisk A/S, has gained popularity for its off-label use, helping users drop excess pounds within a matter of months.

  • PR Newswire

    Lilly ESG Report Highlights Progress Towards Sustainability Goals

    Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to maintaining a strong and resilient company.

  • InvestorPlace

    The 3 Best Momentum Stocks to Buy in May 2023

    Momentum stocks are securities that are rising fast and seeing their gains accelerate. This is often because a given stock has one or more catalysts that have led to a rally in its share price. Catalysts can include strong earnings, regulatory approval of a new product or service, a sizable stake taken by a notable investor. Additionally, there can be hype surrounding a particular economic sector, company or product that’s driving investor demand. Notably, momentum typically indicates underlying

  • Motley Fool

    1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market

    Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.

  • Zacks

    Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

    Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

  • Investor's Business Daily

    Bullish Stock Charts: How To Identify The Cup Without Handle Pattern

    The cup without handle can yield perfectly timed entries and opportune profits, if you do your homework

  • Insider Monkey

    Is Eli Lilly and Company (LLY) an Attractive Growth Stock?

    Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […]

  • Insider Monkey

    25 Most Prescribed Medication in the World

    In this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see the 10 most prescribed medication in the world. The advancements that the medical field has accomplished over the past century, and especially in recent decades, has […]

  • PR Newswire

    Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

    The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms. These data represent the first clinical evidence that stimulating the endogenous PD-1 inhibitory pathway could be an effective approach to treat rheumatologic disease. The phase 2a clinical tri

  • InvestorPlace

    Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs

    Everyone seems to be talking about semiconductors, artificial intelligence (AI) and mega-cap tech. However, no one seems to be talking about healthcare stocks to buy. That said, I get it. Semiconductor stocks and AI stocks are the exciting plays in the market, while mega-cap tech is powering the S&P 500 higher. In fact, just a handful of names have driven almost all of the year-to-date gains in the index.InvestorPlace - Stock Market News, Stock Advice & Trading Tips While these stocks are domina

  • Bloomberg

    Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data

    (Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergHere’s How Much Wealth You Need to Join the Richest 1% GloballyMercedes Sets Out to Make Sexy Vans With Yacht-Like InteriorsJPMorgan Asset Says Markets Are Right to Bet on US Rate CutsDebt-Limit Talks to Intensify as Biden Set to Depart for JapanSeveral major drugmakers keen to expand in immunology have been studying the $23 bi

  • Investor's Business Daily

    Eli Lilly Stock Doesn't Have To Shoot Higher For Profits

    Eli Lilly is taking a little pause after a nice move in the last month. If Eli Lilly stock continues to trade around 440, this calendar spread will profit. A calendar spread is an income trade that involves selling a short-term option and buying a longer-term option with the same strike price.

  • Insider Monkey

    Billionaire Ken Fisher’s Top 15 Dividend Stock Picks

    In this article, we discuss billionaire Ken Fisher’s top 15 dividend stock picks. You can skip our detailed analysis of Fisher’s hedge fund and his investment philosophy, and go directly to read Billionaire Ken Fisher’s Top 5 Dividend Stock Picks. Ken Fisher’s Fisher Asset Management is one of the most prominent hedge funds in America. […]

  • Simply Wall St.

    With 84% ownership of the shares, Eli Lilly and Company (NYSE:LLY) is heavily dominated by institutional owners

    Key Insights Significantly high institutional ownership implies Eli Lilly's stock price is sensitive to their trading...